Findings seen for patients with breast cancer starting a high\/moderate emetogenic chemotherapy regimen<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 2, 2024 (HealthDay News) — Olanzapine may be better than prochlorperazine for reducing refractory nausea in patients with breast cancer starting a high\/moderate emetogenic chemotherapy regimen, according to a study presented at the American Society of Clinical Oncology annual Quality Care Symposium, held from Sept. 27 to 28 in San Francisco.\u00a0<\/p>\n
Luke Joseph Peppone, Ph.D., from the University of Rochester Medical Center in New York, and colleagues randomly assigned 310 chemotherapy-naive patients with breast cancer starting a high\/moderate emetogenic chemotherapy regimen with moderate or worse nausea (\u00e2\u0089\u00a53 on a 1-to-7 scale) in cycle 1 to olanzapine, prochlorperazine, or placebo.<\/p>\n
The researchers found a statistically significant change in average nausea score for the olanzapine (average change, \u00e2\u0088\u00921.07: Cohen’s \u00ce\u0094 = 0.49) and prochlorperazine groups (average change, \u00e2\u0088\u00920.94: Cohen’s \u00ce\u0094 = 0.38) versus the placebo group (average change, \u00e2\u0088\u00920.50). For change in maximum nausea score, similar but larger changes were seen in the olanzapine (maximum change, \u00e2\u0088\u00922.57: Cohen’s \u00ce\u0094 = 0.86) and prochlorperazine arms (maximum change, \u00e2\u0088\u00922.01: Cohen’s \u00ce\u0094 = 0.47) versus the placebo arm (maximum change, \u00e2\u0088\u00921.30). From before chemo to cycle 2, the olanzapine group had a clinically significant change in overall quality of life compared with the placebo group (Functional Assessment of Cancer Therapy-General\u00a0[FACT-G] mean difference, +4.91). However, the prochlorperazine arm did not have significant improvement versus placebo (FACT-G mean difference, \u00e2\u0088\u00920.87). Olanzapine showed superiority versus prochlorperazine for changes in maximum nausea score (mean difference, \u00e2\u0088\u00920.56) and quality of life (FACT-G mean difference, +5.80), but not for average nausea (mean difference, \u00e2\u0088\u00920.13).<\/p>\n
“This study fills the gap in empirical comparisons and solidifies olanzapine’s position as a promising intervention for refractory nausea,” the authors write.<\/p>\n
Several authors disclosed ties to the pharmaceutical industry.<\/p>\n
Press Release<\/a><\/p>\n